24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Startup: Confidential
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Compugen
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
11:44
Teva to pay $450 million over Copaxone price inflation
15:02
Asus Zenbook S 14 embraces AI revolution with Intel's Core Ultra Processor
14:46
Hezbollah missiles threaten Adani's Haifa Port: What happens if Israel’s key trade hub shuts down?
12:57
TechnoPulm raises $2 million to develop a handheld device capable of performing full lung function tests
More stories
Buzz
Most popular
Daily
Weekly
1
Intel employees brace for layoff notices as cuts to move into high gear next week
2
How Intel's $108 billion buyback gambit backfired—a cautionary tale for tech giants
3
"We’ll be looking out for you": Intel CEO Gelsinger stands with Israeli team
4
Bill Ackman sees 80% return on Tel Aviv Stock Exchange investment in just 10 months
5
OpenWeb turmoil: Jeff Horing's role in ousting CEO Nadav Shoval reveals the unicorn industry's dark underbelly
More news
Compugen
5 stories about Compugen
Compugen shares soar on massive deal with Gilead, worth up to $848 million
19.12.23
|
Sophie Shulman
The Israeli company utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies
Compugen Falls 17% on Employee Cuts Announcement
27.02.19
|
Lilach Baumer
The Nasdaq-listed cancer immunotherapy company published its fourth quarter and full year results for 2018 Tuesday
Bristol-Myers Squibb Invests $12 Million in Israeli Immunotherapy Company Compugen
12.10.18
|
Dror Reich
The investment is part of a clinical trial collaboration for a treatment that combines Compugen’s investigational antibody with an immune checkpoint inhibitor from Bristol-Myers Squibb
Biotech Company Compugen Down on Nasdaq Following $21 Million Direct Offering
17.06.18
|
Dror Reich
The Israel-based cancer immunotherapy company intends to use the proceedings for product development
AstraZeneca Signs Deal with Cancer Immunotherapy Company Compugen
03.04.18
|
Lilach Baumer
The deal has the potential to be worth over $200 million for Nasdaq-listed Compugen
Please ensure Javascript is enabled for purposes of
website accessibility